ALLMedicine™ Tardive Dyskinesia Center
Research & Reviews 495 results
Clinical and Experimental Pharmacology & Physiology; Osacka J, Kiss A et. al.
May 17th, 2022 - Antipsychotics are used in the treatment of schizophrenia and other psychiatric disorders. Generally they are divided into typical and atypical ones, according to the fact that atypical antipychotics induce less side effects and are more effective...
Schizophrenia Bulletin; Willems AE, Mentzel CL et. al.
Apr 30th, 2022 - There is a substantial gap in life expectancy between patients with severe mental illness (SMI) and the general population and it is important to understand which factors contribute to this difference. Research suggests an association between tard...
CNS Spectrums; Bera R, Franey E et. al.
Apr 29th, 2022 - As a result of COVID-19, patients and clinicians rapidly shifted to telehealth. An observational survey study, Real-World Tele-Health Evaluation of Tardive Dyskinesia (TD) Symptoms Communication/Observation Procedure Evaluation in Outpatient Clini...
CNS Spectrums; Barkay H, Finkbeiner S et. al.
Apr 29th, 2022 - The mechanism of tardive dyskinesia (TD) is complex and not well understood. Dopamine-receptor blockade in the nigrostriatal pathway may lead to a hyperdopaminergic state that can interfere with mechanisms of movement control, leading to TD. Medic...
CNS Spectrums; Lundt L, Jain R et. al.
Apr 29th, 2022 - MIND-TD is a collaboration of healthcare professionals (HCPs) who are committed to raising awareness of tardive dyskinesia (TD), a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and othe...
Guidelines 1 results
The Journal of Clinical Psychiatry; Kane JM, Correll CU et. al.
May 10th, 2018 - To provide an historic overview of the Abnormal Involuntary Movement Scale (AIMS) in clinical trials of tardive dyskinesia (TD), with current recommendations for analyzing and interpreting AIMS data. Seven psychiatrists and 1 neurologist were sele...
Drugs 151 results see all →
Clinicaltrials.gov 29 results
Apr 20th, 2021 - This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
Mar 12th, 2021 - Tourette Syndrome is typically treated with drugs that block or reduce the function of dopamine (a brain chemical involved in movement). However, many of these drugs have adverse effects including irreversible, involuntary movements, typically aff...
Oct 9th, 2020 - The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Mar 28th, 2019 - Gastrointestinal (GI) symptoms are frequently complained by PD patients. To improve their symptoms, prokinetics are often used in clinics. However, some prokinetics are dopamine receptor antagonist which can aggravate motor symptoms of PD patients...
Mar 26th, 2019 - A number of 173 patients were examined for myofascial pain due to TMD in the Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ankara University between April-August 2018. An informed consent was taken from all the patients after...
News 107 results
Apr 22nd, 2022 - Tardive dyskinesia (TD), according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is a medication-induced movement disorder that causes involuntary repetitive muscle movements in the face, neck, arms, and legs...
Apr 19th, 2022 - A drug currently approved for tardive dyskinesia (TD) is also effective at treating Huntington's disease (HD)–associated chorea, a movement disorder that affects most patients with HD, new phase 3 trial results show. Valbenazine is in the same cla...
Apr 11th, 2022 - Tardive dyskinesia (TD) is a severe, often irreversible movement disorder caused by prolonged exposure to certain medications. The clinical manifestations of TD include abnormal movements of the tongue, lips, face, trunk, and extremities. The invo...
Mar 31st, 2022 - An investigational drug that blocks the dopamine-1 (D1) receptor reduces tics and is safe and well tolerated in children with Tourette syndrome (TS), a new study shows. Importantly, unlike current medications for the disorder, ecocipam does not le...
Feb 18th, 2022 - LAS VEGAS – In the opinion of Christoph U. Correll, MD, tardive dyskinesia (TD) “has been somewhat forgotten” by psychiatrists because the risk of patients developing the condition is considered to be significantly lower with second-generation ant.